12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bioniche, Paladin deal

Bioniche granted Paladin exclusive rights to commercialize Urocidin to treat bladder cancer in Canada, South Africa and Mexico. The companies have agreed to share net revenues, and Bioniche is eligible for sales milestones of up to C$16 million ($15.4 million). Bioniche is responsible for product development and manufacturing costs, and Paladin will be responsible for sales and marketing costs. Late last year, the Endo Pharmaceuticals...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >